Amphastar Pharmaceuticals Inc. Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 10/11/2026)
| Balance Sheet | Total Assets | 1,629,300,000.00 | Equity Ratio | 48.41 % |
| Balance Sheet | Total Equity | 788,805,000.00 | ROA | 6.02 % |
| Cashflow | Capital Expenditures | -34,882,000.00 | P/FCF | 11.00 |
| Cashflow | Free Cash Flow | 121,233,000.00 | – | – |
| Cashflow | Operating Cash Flow | 156,115,000.00 | P/CF | 8.54 |
| Income | Earnings per Share (diluted) | 2.03 | Div. Yield | – |
| Income | Net Income | 98,094,000.00 | P/E | 13.63 |
| Income | Shares Outstanding | 45,645,497.00 | P/B | 1.69 |
| Income | Total Revenue | 719,887,000.00 | P/S | 1.85 |
Ratios calculated on: 11/5/2026
Company Description
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company manufactures and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.ir.amphastar.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more